title: [Coronary angioplasty in acute coronary syndromes: adjuvant drug therapy and management of the bleeding risk due to antithrombotic agents].
abstract: Acute coronary syndromes (ACS) are one of the most dramatic manifestations of atherothrombosis and several efforts have been made in recent years to improve their prognosis. Morbidity and mortality of high-to-medium risk ACS have significantly reduced in the real world setting during the last few years, due to a very aggressive antithrombotic therapy, which always involves a combination of an anticoagulant and different antiplatelet agents, and an extensive indication to revascularization. However, it has become increasingly important for clinicians to identify the correct treatment between the several different combination of antithrombotic and antiplatelet agents. The selection and intensity of these combinations are based in the first instance on the ischemic risk profile of the patient and the treatment strategy (early invasive, delayed invasive or conservative) selected. However, the use of such an aggressive antithrombotic therapy coupled with coronary angioplasty exposes the patients to a significant risk of bleeding. Unfortunately, these bleeding complications have a negative prognostic significance and force clinicians to suspend (or decrease) the antithrombotic treatments to control bleeding.
authors.affiliation: U.O. di Cardiologia, Azienda USL, Ospedale Maggiore, Bologna.
authors.forename: Silvia
authors.initials: S
authors.lastname: Zagnoni
authors.forename: Gianni
authors.initials: G
authors.lastname: Casella
authors.forename: Anna Chiara
authors.initials: AC
authors.lastname: Musuraca
authors.forename: Daniela
authors.initials: D
authors.lastname: Calabrese
authors.forename: Pier Camillo
authors.initials: PC
authors.lastname: Pavesi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Pasquale
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D012307:Risk Factors
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents